IFN- γ and TNF- α drive a CXCL10 + CCL2 + macrophage phenotype expanded in severe COVID-19 and other diseases with tissue inflammation
This article has been Reviewed by the following groups
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
- Evaluated articles (ScreenIT)
Abstract
Immunosuppressive and anti-cytokine treatment may have a protective effect for patients with COVID-19. Understanding the immune cell states shared between COVID-19 and other inflammatory diseases with established therapies may help nominate immunomodulatory therapies. Using an integrative strategy, we built a reference by meta-analyzing > 300,000 immune cells from COVID-19 and 5 inflammatory diseases including rheumatoid arthritis (RA), Crohn’s disease (CD), ulcerative colitis (UC), lupus, and interstitial lung disease. Our cross-disease analysis revealed that an FCN1 + inflammatory macrophage state is common to COVID-19 bronchoalveolar lavage samples, RA synovium, CD ileum, and UC colon. We also observed that a CXCL10 + CCL2 + inflammatory macrophage state is abundant in severe COVID-19, inflamed CD and RA, and expresses inflammatory genes such as GBP1, STAT1 , and IL1B . We found that the CXCL10 + CCL2 + macrophages are transcriptionally similar to blood-derived macrophages stimulated with TNF- α and IFN- γ ex vivo . Our findings suggest that IFN- γ , alongside TNF- α , might be a key driver of this abundant inflammatory macrophage phenotype in severe COVID-19 and other inflammatory diseases, which may be targeted by existing immunomodulatory therapies.
Article activity feed
-
SciScore for 10.1101/2020.08.05.238360: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
No key resources detected.
Results from OddPub: Thank you for sharing your code.
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title NCT04337359 No longer available Ruxolitinib Managed Access Program (MAP) for Patients Diagno… NCT04359290 Active, not recruiting Ruxolitinib for Treatment … SciScore for 10.1101/2020.08.05.238360: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
No key resources detected.
Results from OddPub: Thank you for sharing your code.
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title NCT04337359 No longer available Ruxolitinib Managed Access Program (MAP) for Patients Diagno… NCT04359290 Active, not recruiting Ruxolitinib for Treatment of Covid-19 Induced Lung Injury AR… NCT04348695 Recruiting Study of Ruxolitinib Plus Simvastatin in the Prevention and … Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
SciScore for 10.1101/2020.08.05.238360: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
NIH rigor criteria are not applicable to paper type.Table 2: Resources
Experimental Models: Organisms/Strains Sentences Resources trea IFN IL FNh fi h fibTN rea IFN IL t d i t ti it wi wi Un an w w w Un -γ -α α -γ α F- IFN FFN TNF N I T nd a -α F TN CCL23 15 4 2 0 Fold change, TNF-α (vs untreated) f CCL2 IDO1 CXCL10 AN MRC1 4 3 2 1 0 P9 3 2 1 0 1A CXCL9 CLEC4A 3 2 1 0 ● ● γ o γ γ α d N- fibr fibro F- ate N-β L-4 N- ro - ro ro -α ed -β 4 N I IF fib FN ib ib F at N Lth ith T ntre IF d ith I ith f ith f TNtre IF I n w a w U Un α α γwαw F- N-γ w w w Un -γ -α α -γ α F-suggested: NoneRes…
SciScore for 10.1101/2020.08.05.238360: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
NIH rigor criteria are not applicable to paper type.Table 2: Resources
Experimental Models: Organisms/Strains Sentences Resources trea IFN IL FNh fi h fibTN rea IFN IL t d i t ti it wi wi Un an w w w Un -γ -α α -γ α F- IFN FFN TNF N I T nd a -α F TN CCL23 15 4 2 0 Fold change, TNF-α (vs untreated) f CCL2 IDO1 CXCL10 AN MRC1 4 3 2 1 0 P9 3 2 1 0 1A CXCL9 CLEC4A 3 2 1 0 ● ● γ o γ γ α d N- fibr fibro F- ate N-β L-4 N- ro - ro ro -α ed -β 4 N I IF fib FN ib ib F at N Lth ith T ntre IF d ith I ith f ith f TNtre IF I n w a w U Un α α γwαw F- N-γ w w w Un -γ -α α -γ α F-suggested: NoneResults from OddPub: Thank you for sharing your code.
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
-
